Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Fourth Quarter Earnings
April 09 2007 - 4:30PM
PR Newswire (US)
NEW YORK, April 9 /PRNewswire/ -- Forest Laboratories, Inc.
(NYSE:FRX), an international manufacturer and marketer of
pharmaceutical products, will release its Fiscal 2007 Fourth
Quarter financial results before the U.S. stock market opens on
Tuesday, April 24, 2007. Later that day, at 10:00 AM EDT, Forest
will host a conference call where Dr. Lawrence Olanoff, President
and Chief Operating Officer and Frank Perier, Senior Vice President
and Chief Financial Officer, will discuss the financial results and
relevant company and industry topics. The conference call will be
webcast live beginning at 10:00 AM EDT on the Company's website
http://www.frx.com/ and also on the website
http://www.streetevents.com/. Please log on to either website at
least fifteen minutes prior to the conference call as it may be
necessary to download software to access the call. A replay of the
conference call will be available until May 2, 2007 at both
websites and also by dialing 1-800-642- 1687 (US investors) or
+1-706-645-9291 (international investors), ID 5376257. About Forest
Laboratories and Its Products Forest Laboratories
(http://www.frx.com/) is a U.S.-based pharmaceutical company
dedicated to identifying, developing, and delivering products that
make a positive difference in peoples' lives. Forest Laboratories'
growing product line includes Lexapro(R) (escitalopram oxalate), an
SSRI indicated for adults for the initial and maintenance treatment
of major depressive disorder and for generalized anxiety disorder;
Namenda(R) (memantine HCl), an N-methyl-D- aspartate
(NMDA)-receptor antagonist indicated for the treatment of moderate
and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil),
an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan
medoxomil- hydrochlorothiazide), an angiotensin receptor blocker
and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated
in combination with psychosocial support for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation. *Benicar is a registered
trademark of Daiichi Sankyo, and Campral is a registered trademark
of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt,
Germany. Except for the historical information contained herein,
this release contains "forward-looking statements" within the
meaning of the Private Securities Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, acceptance and demand
for new pharmaceutical products, the impact of competitive products
and pricing, the timely development and launch of new products and
the risk factors listed from time to time in the Company's SEC
reports, including the Company's Annual Report on Form 10-K for the
fiscal year ended March 31, 2006 and on Form 10-Q for the periods
ended June 30, 2006 and September 20, 2006. DATASOURCE: Forest
Laboratories, Inc. CONTACT: Charles E. Triano, Vice President --
Investor Relations, of Forest Laboratories, Inc., +1-212-224-6714,
or Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024